Alternatives for reducing relapse rate when switching from natalizumab to fingolimod in multiple sclerosis

Expert Review of Clinical Pharmacology
Yara Dadalti FragosoVera Lucia Ferreira Vieira

Abstract

Natalizumab is a therapeutic option for treating multiple sclerosis (MS) and is particularly efficacious for patients with highly active disease. A long washout period has been recommended between withdrawal of natalizumab and start of fingolimod (another option for treating MS). This long washout period has been associated with a significant increase in MS activity. In the present study, a group of 96 patients who were switched from natalizumab to fingolimod had short washout periods between drugs, or monthly corticosteroid pulse therapy if longer washout periods were recommended. This therapeutic approach led to the lowest reported relapse rate so far, among patients with MS switching from natalizumab to fingolimod (8.3%). No complications from short withdrawal were observed in this group of patients.

References

Mar 3, 2006·The New England Journal of Medicine·Richard A RudickUNKNOWN SENTINEL Investigators
Sep 8, 2010·Annals of Neurology·Joseph R BergerTjalf Ziemssen
Nov 8, 2011·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·G BorrielloC Pozzilli
Dec 21, 2011·Multiple Sclerosis : Clinical and Laboratory Research·Theo RispensJoep Killestein
Jun 30, 2012·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·S RossiD Centonze
Aug 22, 2012·Multiple Sclerosis : Clinical and Laboratory Research·L DaelmanA Tourbah
Oct 27, 2012·Neurology·Valérie RigauEric Thouvenot
Oct 27, 2012·Multiple Sclerosis : Clinical and Laboratory Research·Sebastian JanderHans-Peter Hartung
Nov 28, 2012·Multiple Sclerosis : Clinical and Laboratory Research·A LaroniGl Mancardi
Jan 12, 2013·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Jeremy Chataway, David H Miller
Jan 23, 2013·Acta Neurologica Scandinavica·A P SempereE Feliu-Rey
Apr 9, 2013·Arquivos de neuro-psiquiatria·Yára Dadalti FragosoMassaco Satomi
Jun 1, 2013·Multiple Sclerosis : Clinical and Laboratory Research·Jérôme de SezeUNKNOWN Alsacep Network
Dec 25, 2013·Multiple Sclerosis : Clinical and Laboratory Research·Elisabeth MaillartCaroline Papeix
Jan 15, 2014·Expert Review of Neurotherapeutics·Yara D FragosoCarla R A V Stella
Jan 22, 2014·Journal of Internal Medicine·A H Cross, R T Naismith
Feb 26, 2014·JAMA Neurology·Mikael CohenUNKNOWN Club Francophone de la Sclérose en Plaques Investigators
Mar 13, 2014·Neurology·Vilija G JokubaitisUNKNOWN MSBase Study Group
Apr 12, 2014·Acta Neurologica Scandinavica·S Salhofer-PolanyiF Leutmezer
May 21, 2014·Nature Reviews. Neurology·Martin Stangel, Olaf Stüve
May 21, 2014·Multiple Sclerosis : Clinical and Laboratory Research·Robert HoepnerIngo Kleiter
Jun 20, 2014·CNS Drugs·Carmen Tur, Xavier Montalban
Jul 6, 2014·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·M CapobiancoA Bertolotto
Sep 25, 2014·Arquivos de neuro-psiquiatria·Yara Dadalti FragosoCarlos Bernardo Tauil
Sep 27, 2014·Multiple Sclerosis : Clinical and Laboratory Research·G ComiL Kappos
Oct 12, 2014·Multiple Sclerosis : Clinical and Laboratory Research·Delphine PeaureauxDavid Brassat
May 31, 2015·Neurology·Ludwig KapposUNKNOWN TOFINGO study group
Nov 5, 2015·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·G FurneriL Prosperini

❮ Previous
Next ❯

Citations

Jan 5, 2017·European Neurology·Ramón Villaverde-GonzálezAntonio Candeliere Merlicco
Jan 22, 2017·Clinical Immunology : the Official Journal of the Clinical Immunology Society·Andrea HarrerPeter Wipfler
Aug 25, 2016·Arquivos de neuro-psiquiatria·Yara Dadalti FragosoThereza Cristina d'Avila Winckler
Jun 13, 2018·The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques·Mark S FreedmanPaul S Giacomini

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Farmacia hospitalaria : órgano oficial de expresión científica de la Sociedad Española de Farmacia Hospitalaria
Julia Sánchez-GundínLourdes Gómez Romero
JAMA Neurology
Mikael CohenClub Francophone de la Sclérose en Plaques Investigators
Multiple Sclerosis : Clinical and Laboratory Research
Jérôme de SezeAlsacep Network
© 2022 Meta ULC. All rights reserved